Valuation: GH Research PLC

Market Cap 1.43B 1.28B 1.18B 1.07B 2B 136B 2.04B 14.07B 5.65B 71.52B 5.37B 5.26B 226B P/E 2026 *
-17.4x
P/E 2027 * -11.4x
Enterprise Value 1.11B 998M 918M 831M 1.55B 106B 1.58B 10.94B 4.39B 55.63B 4.18B 4.09B 175B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
75.54%
Yield 2026 *
-
Yield 2027 * -
1 day-2.98%
1 week+15.44%
Current month-11.16%
1 month-11.16%
3 months-26.50%
6 months+1.61%
Current year+64.25%
1 week 18.06
Extreme 18.065
22.13
1 month 17.54
Extreme 17.54
23.12
Current year 12.77
Extreme 12.77
31.44
1 year 12.04
Extreme 12.04
31.44
3 years 5.05
Extreme 5.05
31.44
5 years 5.05
Extreme 5.05
31.44
10 years 5.05
Extreme 5.05
31.44
Manager TitleAgeSince
Chief Executive Officer 51 2024-09-02
Corporate Officer/Principal 29 2020-10-31
Director of Finance/CFO 40 2020-12-31
Director TitleAgeSince
Chairman 57 2017-12-31
Director/Board Member 60 2020-11-30
Director/Board Member 61 2021-09-23
Date Insider Type Main position Quantity % Market Cap. Importance
9/8/26 Free

Founder

2,303 0.0034%
8/11/26 Free

Director

2,202 0.0032%
8/11/26 Free

Director

102,202 0.1491%
Change 5-day change 1-year change 3-year change Capi.($)
-2.98%+15.44%+66.35%+180.00% 1.43B
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average +0.01%+8.33%+49.71%+203.69% 39.58B
Weighted average by Cap. +0.17%+5.48%+48.57%+186.11%

Financials

2026 *2027 *
Net sales - -
Net income -80.99M -72.54M -66.72M -60.46M -113M -7.69B -115M -796M -319M -4.05B -304M -297M -12.76B -132M -118M -109M -98.62M -184M -12.55B -188M -1.3B -521M -6.6B -496M -485M -20.81B
Net Debt -318M -285M -262M -237M -444M -30.19B -452M -3.12B -1.25B -15.88B -1.19B -1.17B -50.09B -298M -267M -246M -223M -416M -28.31B -424M -2.93B -1.18B -14.89B -1.12B -1.1B -46.96B
Projected Income Statement - Annual - GH Research PLC
Logo GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is focusing on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD). Its portfolio includes GH001, its proprietary inhalable mebufotenin product candidate and GH002, its proprietary intravenous mebufotenin product candidate. GH001 is delivered via a vaporization device produced by a third party, and the Company is developing a proprietary aerosol delivery device which is in clinical investigation in Europe. GH001 completed two Phase 1 clinical trials in healthy volunteers, a Phase 1/2 trial in TRD and two Phase 2a proof-of-concept trials. GH002 Completed a randomized, double-blind, placebo-controlled, dose-ranging clinical pharmacology trial of GH002 in healthy volunteers, and it is developing GH002 within its focus area of psychiatric and neurological disorders.
Employees
73
Date Price Change Volume
26-10-30 US$20.86 -2.98% 305,401
26-10-29 US$21.50 +3.81% 345,218
26-10-28 US$20.71 +3.45% 198,764
26-10-27 US$20.02 +4.38% 299,979
26-10-26 US$19.18 +6.14% 306,079
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - GH Research PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
20.86USD
Average target price
42.89USD
Spread / Average Target
+105.60%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - GH Research PLC
  1. Stock Market
  2. Stocks
  3. GHRS Stock